ReviewBiomedicines2026
Roles of Extracellular Vesicle-Derived microRNAs in Metabolic Dysfunction-Associated Steatotic Liver Disease to Hepatocellular Carcinoma.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease, and has emerged as a common etiological factor for hepatocellular carcinoma (HCC). MASLD and MASLD-associated HCC lack specific clinical biomarkers. Extracellular vesicles (EVs) and their microRNA (miRNA) cargo have emerged as key mediators of intercellular communication and promising diagnostic tools. This review provides a systematic overview of the stage-specific roles of EV-derived miRNAs across the MASLD spectrum. We focus on how key EV-miRNAs regulate lipid metabolism, inflammatory responses, hepatic stellate cell (HSC) activation, and the remodeling of the tumor microenvironment (TME). This review provides an updated perspective on cross-stage EV-derived miRNA regulatory circuits. In addition, we critically evaluate the potential of EV-derived miRNAs as non-invasive biomarkers and therapeutic targets. By integrating mechanistic insights with clinical relevance, this review provides a comprehensive framework for the early identification, risk stratification, and precision intervention of MASLD-associated HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.